Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: Evidence for Wnt pathway implication

International Journal of Cancer

Volumn 124, Issue 1, 2009, Pages 103-108

  Kastritis, Efstathios ^a,d   Murray, Samuel ^b   Kyriakou, Fani ^a   Horti, Maria ^c   Tamvakis, Nicolaos ^a   Kavantzas, Nicolaos ^a   Patsouris, Efstratios S ^a   Noni, Aphrodite ^c   Legaki, Sofia ^c   Dimopoulos, Meletios A ^a   Bamias, Aristotle ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b METROPOLITAN HOSPITAL CENTER   (United States)

^c SISMANOGLIO HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

Author keywords

Adenomatous polyposis coli; Adjuvant chemotherapy; Carboplatin; Paclitaxel; Prognosis; Urothelial cancer

Indexed keywords

APC PROTEIN; BETA CATENIN; CARBOPLATIN; CYCLOOXYGENASE 2; ENDOGLIN; KI 67 ANTIGEN; PACLITAXEL; PROTEIN P53; WNT PROTEIN; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; BLADDER CANCER; CELL PROLIFERATION; CONTROLLED STUDY; CYSTECTOMY; DISEASE FREE INTERVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MULTIPLE CYCLE TREATMENT; MUSCLE DISEASE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; UROGENITAL TRACT CANCER; BIOSYNTHESIS; BLADDER TUMOR; CARCINOMA; CELL NUCLEUS; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; MUTATION; PATHOLOGY; UROTHELIUM;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ADULT; AGED; ANTINEOPLASTIC AGENTS; BETA CATENIN; CARBOPLATIN; CARCINOMA; CELL NUCLEUS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PACLITAXEL; URINARY BLADDER NEOPLASMS; UROTHELIUM; WNT PROTEINS;

EID: 58149383087     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23917     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Clark PE. Bladder cancer. Curr Opin Oncol 2007;19:241-7.
3. Parekh DJ, Bochner BH, Dalbagni G. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. J Clin Oncol 2006;24:5519-27.
4. Schulz WA. Understanding urothelial carcinoma through cancer pathways. Int J Cancer 2006;119:1513-8.
5. Egawa S, Kuruma H. Search for biomarkers of aggressiveness in bladder cancer. Eur Urol 2006;50:20-2.
6. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 2006;24:5552-64.
7. Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, Kogevinas M, Real FX. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005;6:678-86.
8. Kleber M, Sommer L. Wnt signaling and the regulation of stem cell function. Curr Opin Cell Biol 2004;16:681-7.
9. Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis P. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci USA 1995;92:3046-50.
10. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-51.
11. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D, et al. Identification of FAP locus genes from chromosome 5q21. Science 1991;253: 661-5.
12. Cottrell S, Bicknell D, Kaklamanis L, Bodmer WF. Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas. Lancet 1992;340:626-30.
13. Rubinfeld B, Souza B, Albert I, Muller O, Chamberlain SH, Masiarz FR, Munemitsu S, Polakis P. Association of the APC gene product with beta-catenin. Science 1993;262:1731-4.
14. Nathke I. APC at a glance. J Cell Sci 2004;117 (pt 21):4873-5.
15. Miyamoto H, Shuin T, Ikeda I, Hosaka M, Kubota Y. Loss of heterozygosity at the p53, RB, DCC and APC tumor suppressor gene loci in human bladder cancer. J Urol 1996;155:1444-7.
16. Bohm M, Kirch H, Otto T, Rubben H, Wieland I. Deletion analysis at the DEL-27, APC and MTS1 loci in bladder cancer: LOH at the DEL- 27 locus on 5p13-12 is a prognostic marker of tumor progression. Int J Cancer 1997;74:291-5.
17. Stoehr R, Krieg RC, Knuechel R, Hofstaedter F, Pilarsky C, Zaak D, Schmitt R, Hartmann A. No evidence for involvement of beta-catenin and APC in urothelial carcinomas. Int J Oncol 2002;20:905-11.
18. Shiina H, Igawa M, Urakami S, Shigeno K, Yoneda T, Terashima M, Deguchi M, Ribeiro-Filho L, Dahiya R. Alterations of beta- and gamma-catenin in N-butyl-N-(-4-hydroxybutyl)nitrosamine-induced murine bladder cancer. Cancer Res 2001;61:7101-9.
19. Shiina H, Igawa M, Shigeno K, Terashima M, Deguchi M, Yamanaka M, Ribeiro-Filho L, Kane CJ, Dahiya R. Beta-catenin mutations correlate with over expression of C-myc and cyclin D1 genes in bladder cancer. J Urol 2002;168:2220-6.
20. Shimazui T, Schalken JA, Giroldi LA, Jansen CF, Akaza H, Koiso K, Debruyne FM, Bringuier PP. Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. Cancer Res 1996;56:4154-8.
21. Nakopoulou L, Zervas A, Gakiopoulou-Givalou H, Constantinides C, Doumanis G, Davaris P, Dimopoulos C. Prognostic value of E-cadherin, beta-catenin, P120ctn in patients with transitional cell bladder cancer. Anticancer Res 2000;20:4571-8.
22. Zhu X, Kanai Y, Saito A, Kondo Y, Hirohashi S. Aberrant expression of beta-catenin and mutation of exon 3 of the beta-catenin gene in renal and urothelial carcinomas. Pathol Int 2000;50:945-52.
23. Garcia del Muro X, Torregrosa A, Munoz J, Castellsague X, Condom E, Vigues F, Arance A, Fabra A, Germa JR. Prognostic value of the expression of E-cadherin and beta-catenin in bladder cancer. Eur J Cancer 2000;36:357-62.
24. Kashibuchi K, Tomita K, Schalken JA, Kume H, Yamaguchi T, Muto S, Horie S, Kitamura T. The prognostic value of E-cadherin, alpha-, beta-, and gamma-catenin in urothelial cancer of the upper urinary tract. Eur Urol 2006;49:839-45; discussion 45.
25. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007;17:45-51.
26. Bamias A, Deliveliotis C, Aravantinos G, Kalofonos C, Karayiannis A, Dimopoulos MA. Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced bladder cancer: a study by the Hellenic Cooperative Oncology Group. J Urol 2004;171:1467-70.
27. Rubinfeld B, Albert I, Porfiri E, Munemitsu S, Polakis P. Loss of beta-catenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the gene. Cancer Res 1997;57:4624-30.
28. Kishida S, Yamamoto H, Ikeda S, Kishida M, Sakamoto I, Koyama S, Kikuchi A. Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of beta-catenin. J Biol Chem 1998;273:10823-6.
29. Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S, Aoki T, Miki Y, Mori T, Nakamura Y. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1992;1:229-33.
30. Murray S, Timotheadou E, Linardou H, Vrettou AV, Kostopoulos I, Skrickova J, Papakostantinou C, Christodoulou C, Pectasides D, Samantas E, Papakostas P, Skarlos DV, et al. Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients. Lung Cancer 2006;52:225-33.
31. Fearnhead NS, Wilding JL, Winney B, Tonks S, Bartlett S, Bicknell DC, Tomlinson IP, Mortensen NJ, Bodmer WF. Multiple rare variants in different genes account for multifactorial inherited susceptibility to colorectal adenomas. Proc Natl Acad Sci USA 2004;101:15992-7.
32. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275:1787-90.
33. Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. Hum Mol Genet 2001;10:721-33.
34. Frenette PS, Atweh GF. Sickle cell disease: old discoveries, new concepts, and future promise. J Clin Invest 2007;117:850-8.
35. Yates DR, Rehman I, Abbod MF, Meuth M, Cross SS, Linkens DA, Hamdy FC, Catto JW. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res 2007;13:2046-53.
36. Eisinger AL, Nadauld LD, Shelton DN, Peterson PW, Phelps RA, Chidester S, Stafforini DM, Prescott SM, Jones DA. The adenomatous polyposis coli tumor suppressor gene regulates expression of cyclooxygenase-2 by a mechanism that involves retinoic acid. J Biol Chem 2006;281:20474-82.
37. Wang D, Mann JR, DuBois RN. WNT and cyclooxygenase-2 crosstalk accelerates adenoma growth. Cell Cycle 2004;3:1512-5.
38. Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M, Miura K, Harris CC. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 2003;63:728-34.
39. Buchanan FG, DuBois RN. Connecting COX-2 and Wnt in cancer. Cancer Cell 2006;9:6-8.
40. Catto JW, Azzouzi AR, Rehman I, Feeley KM, Cross SS, Amira N, Fromont G, Sibony M, Cussenot O, Meuth M, Hamdy FC. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 2005;23:2903-10.
41. Hartmann A, Zanardo L, Bocker-Edmonston T, Blaszyk H, Dietmaier W, Stoehr R, Cheville JC, Junker K, Wieland W, Knuechel R, Rueschoff J, Hofstaedter F, et al. Frequent microsatellite instability in sporadic tumors of the upper urinary tract. Cancer Res 2002;62:6796-802.
42. Amira N, Rivet J, Soliman H, Cancel-Tassin G, Le Duc A, Janin A, Cussenot O. Microsatellite instability in urothelial carcinoma of the upper urinary tract. J Urol 2003;170(4 pt 1):1151-4.
43. Catto JW, Azzouzi AR, Amira N, Rehman I, Feeley KM, Cross SS, Fromont G, Sibony M, Hamdy FC, Cussenot O, Meuth M. Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. Oncogene 2003;22:8699-706.